Used in immunotherapy research and development, particularly in oncology. It targets the LILRB2 receptor, which plays a role in suppressing immune responses in the tumor microenvironment. By blocking this receptor, the antibody helps restore the activity of immune cells like T cells and natural killer cells, enhancing their ability to attack cancer cells. It is being investigated in combination with other immunotherapies such as PD-1/PD-L1 inhibitors to improve anti-tumor efficacy. Also serves as a reference standard in antibody development and immunoassay validation for consistency and performance benchmarking.